What's the point: Geely star hepatitis C drug sovaldi in India has an official offer of only $900 per 12 week course

Source: U.S - China drug source January 18, 2015 according to Bloomberg news, the Patent Office of India rejected a key patent application of Geely's scientific anti hepatitis C drug sovaldi As a result, Gilead In India had to bear the pain of competing with the generic manufacturers, pushing the price of sovaldi to the level of generic drugs, charging only $900 per 12 week course, while the price of the same course in the United States is as high as $84000 The Patent Office of India once again rejected the key patent application of a star product in India "without any suspense" in accordance with the provisions of the patent law of India on "requirements for new forms of known compounds show better efficacy than the original forms" Although the same patent application has been approved by patent offices of 17 countries, such as China, Israel and Indonesia, the Indian patent office is not moved, "strictly abide by the standards of Indian Patent Law Review" Pfizer, Novartis, and Roche have previously been denied patent applications for several heavyweight products because of the same "stricter innovation standards" in India In addition, the Indian government also strictly limits the price of drugs to ensure that the poorest patients can afford to use them Of course, Gilead will appeal according to the procedure, but there is no hope for the appeal Gilead has stated that the $900 per session sales plan will not change regardless of the outcome of the appeal India's 12 million hepatitis C patients are happy, but even if the price drops to $900 per 12 week course, they may not all be able to afford it Hepatitis C patients in the United States are even more dissatisfied The protests of so many patients and organizations are far less effective than a patent office document The price of the same medicine is 1% in India How can it be At the same time, NATCO pharmaceutical is also pleased NATCO has long been on the lookout for a knockoff version of sovaldi for the Indian market However, NATCO may not achieve what it wants, because Geely has set the price of sovaldi to the price level of generic drugs, and NATCO has to face seven authorized companies from cadilla healthcare, Cipla, hetero labs, mylan laboratories, Ranbaxy laboratories, sequential scientific and structures arcolab, etc to 91 Competition from cheap sovaldi companies in developing countries Unfortunately, China is not on the list of 91 developing countries.